Prescription Revision's Podcast

In this podcast on chronic kidney disease, Dr Paul Ryan will discuss the introduction of both ACE & SGLT2 inhibitors in patients with raised A:C ratios.

Dr Paul Ryan will discuss why now the duration of antibiotics is 5 days rather than 7 days in treating common conditions seen in Primary Care. 

Dr Paul Ryan will discuss Formoterol Budesonide dry powder inhalers and which inhalers are currently available. He will discuss why the maximum dose is 12 puffs once daily. He will also discuss anti-inflammatory reliever therapy & MART therapy & stepping up and stepping down treatment. Finally, he will discuss the risk of osteoporosis after repeated courses of oral steroids.

Dr Paul Ryan will discuss the role of Montelukast and Tiotropium Mist Inhaler in the management of asthma.

Dr Paul Ryan will discuss the management of asthma in children as per the NICE, SIGN & BTS guidelines. He will also discuss the use of a spacer inhaler and the risk of inhaled steroids affecting growth in children. Finally, he will discuss the children who are likely to grow out of asthma and the MART action plan. 

Dr Paul Ryan will discuss the management of asthma in adults in 2025. He will discuss the use of anti-inflammatory medication rather than salbutamol and he will also discuss MART therapy.

Dr Paul Ryan will discuss the diagnosis of asthma in both adults & children in 2025, including the history. He will also discuss the objective test to be done and a reminder that asthma diagnosis is made by a combination of both the suggested history and an objective test. 

Dr Paul Ryan will discuss anticholinergic medication adverse effects, which include:

• Reduced cognition and the risk of dementia
• Major adverse cardiac events

 Dr Paul Ryan will discuss influenza in children & the importance of vaccinating children against influenza. He will also discuss the live attenuated vaccine and the side effects 

Dr Paul Ryan will discuss the efficacy of the influenza vaccination. He will also discuss antigenic drift versus antigenic shift. Finally, he will discuss the recommended groups for vaccination.